多价肺炎链球菌荚膜多糖-蛋白结合疫苗的研究进展  

Progress in research on multivalent Streptococcus pneumoniae capsular polysaccharide-protein conjugate vaccine

作　　者：田雨 马可(综述) 苏晓叶(审校) TIAN Yu;MA Ke;SU Xiao-ye(Beijing Zhifei Lvzhu Biopharmaceutical Co.,Ltd.,Beijing 100176,China)

机构地区：[1]北京智飞绿竹生物制药有限公司,北京100176

出　　处：《中国生物制品学杂志》2022年第10期1268-1273,共6页Chinese Journal of Biologicals

基　　金：国家科技重大专项(2018ZX09738-006)。

摘　　要：肺炎链球菌是人类致病率及死亡率极高的致病菌之一,严重威胁人类的生命健康。肺炎链球菌荚膜多糖具有良好的免疫原性,可激发机体产生保护性抗体,但单纯的荚膜多糖疫苗不能诱导产生免疫记忆抗体,将多糖与载体蛋白结合后可诱导产生记忆性抗体,有效提高疫苗的免疫原性,预防肺炎链球菌入侵性疾病。目前,7、10及13价肺炎链球菌多糖-蛋白结合疫苗(简称肺炎结合疫苗)已相继问世,15及20价肺炎结合疫苗处于临床研发阶段。本文就肺炎结合疫苗研发、制备方法、免疫原性影响因素及国内接种情况等方面的研究进展作一综述。Streptococcus pneumoniae is one of the pathogenic bacteria causing extremely high morbidity and mortality,which seriously threatens human life and health. The capsular polysaccharide of S. pneumoniae is immunogenic,which may stimulate the production of protective antibody. However,capsular polysaccharide vaccines can not induce immune memory antibody alone. The polysaccharide combined with carrier protein may induce immune memory antibody and effectively improve the immunogenicity of vaccine to prevent the invasive disease of S. pneumoniae. At present,heptavalent,decavalent and 13-valent S. pneumoniae polysaccharide-protein conjugate vaccines(pneumococcal conjugate vaccines) have been developed successively,while 15-and 20-valent pneumococcal conjugate vaccines are also in clinical trials. This article reviews the progress in research on development,preparation methods,influencing factors of immunogenicity and vaccination status in China of pneumococcal conjugate vaccine.

关 键 词：多价肺炎链球菌荚膜多糖-蛋白结合疫苗 载体蛋白 免疫原性 

分 类 号：R392.9[医药卫生—免疫学]